Financial Express (Holdings) Limited (“we”, “our”, “us” and derivatives) are committed to protecting and respecting your privacy. This Privacy Policy, together with our Terms of Use, sets out the basis on which any personal data that we collect from you, or that you provide to us, will be processed by us relating to your use of any of the below websites (“sites”).


For the purposes of the Data Protection Act 1998, the data controller is Trustnet Limited of 2nd Floor, Golden House, 30 Great Pulteney Street, London, W1F 9NN. Our nominated representative for the purpose of this Act is Kirsty Witter.


We collect information about you when you register with us or use any of our websites / services. Part of the registration process may include entering personal details & details of your investments.

We may collect information about your computer, including where available your operating system, browser version, domain name and IP address and details of the website that you came from, in order to improve this site.

You confirm that all information you supply is accurate.


In order to provide personalised services to and analyse site traffic, we may use a cookie file which is stored on your browser or the hard drive of your computer. Some of the cookies we use are essential for the sites to operate and may be used to deliver you different content, depending on the type of investor you are.

You can block cookies by activating the setting on your browser which allows you to refuse the setting of all or some cookies. However, if you use your browser settings to block all cookies (including essential cookies) you may not be able to access all or part of our sites. Unless you have adjusted your browser setting so that it will refuse cookies, our system will issue cookies as soon as you visit our sites.


We store and use information you provide as follows:

  • to present content effectively;
  • to provide you with information, products or services that you request from us or which may interest you, tailored to your specific interests, where you have consented to be contacted for such purposes;
  • to carry out our obligations arising from any contracts between you and us;
  • to enable you to participate in interactive features of our service, when you choose to do so;
  • to notify you about changes to our service;
  • to improve our content by tracking group information that describes the habits, usage, patterns and demographics of our customers.

We may also send you emails to provide information and keep you up to date with developments on our sites. It is our policy to have instructions on how to unsubscribe so that you will not receive any future e-mails. You can change your e-mail address at any time.

In order to provide support on the usage of our tools, our support team need access to all information provided in relation to the tool.

We will not disclose your name, email address or postal address or any data that could identify you to any third party without first receiving your permission.

However, you agree that we may disclose to any regulatory authority to which we are subject and to any investment exchange on which we may deal or to its related clearing house (or to investigators, inspectors or agents appointed by them), or to any person empowered to require such information by or under any legal enactment, any information they may request or require relating to you, or if relevant, any of your clients.

You agree that we may pass on information obtained under Money Laundering legislation as we consider necessary to comply with reporting requirements under such legislation.


We want to ensure that the personal information we hold about you is accurate and up to date. You may ask us to correct or remove information that is inaccurate.

You have the right under data protection legislation to access information held about you. If you wish to receive a copy of any personal information we hold, please write to us at 3rd Floor, Hollywood House, Church Street East, Woking, GU21 6HJ. Any access request may be subject to a fee of £10 to meet our costs in providing you with details of the information we hold about you.


The data that we collect from you may be transferred to, and stored at, a destination outside the European Economic Area (“EEA”). It may be processed by staff operating outside the EEA who work for us or for one of our suppliers. Such staff may be engaged in, amongst other things, the provision of support services. By submitting your personal data, you agree to this transfer, storing and processing. We will take all steps reasonably necessary, including the use of encryption, to ensure that your data is treated securely and in accordance with this privacy policy.

Unfortunately, the transmission of information via the internet is not completely secure. Although we will do our best to protect your personal data, we cannot guarantee the security of your data transmitted to our sites; any transmission is at your own risk. You will not hold us responsible for any breach of security unless we have been negligent or in wilful default.


Any changes we make to our privacy policy in the future will be posted on this page and, where appropriate, notified to you by e-mail.


Our sites contain links to other websites. If you follow a link to any of these websites, please note that these websites have their own privacy policies and that we do not accept any responsibility or liability for these policies. Please check these policies before you submit any personal data to these websites.


If you want more information or have any questions or comments relating to our privacy policy please email [email protected] in the first instance.

 Information  X 
Enter a valid email address

Thomson Reuters (TRIL)

  Print      Mail a friend

Tuesday 29 April, 2008

Thomson Reuters

New Thomson Reuters Biomarkers Report Shines a ...

PHILADELPHIA and LONDON, April 29 /PRNewswire/ --

    - Biomarkers to Open the Door to Personalized Medicine and Represents a
Seismic Shift for the Pharma Industry

    The Scientific business of Thomson Reuters today announced the launch of
a new biomarkers report, "Establishing the Standards in Biomarker Research"
which gives a detailed introduction to the world of biomarkers, an overview
of the regulatory context surrounding them, and highlights ongoing biomarker
research in some of the world's leading Pharma companies.

(Logo: )

    Thomson Reuters has chosen to highlight advances in biomarker research
because of its capacity to change the way Pharma companies do business.
Biomarkers which are blood-based tests, gene sequences or mutations, mRNA
expression profiles or tissue proteins, provide unparalleled evidence of the
state of an organism, or indicate normal biological processes, pathogenic
processes or pharmacological responses to a therapeutic intervention.

    "Biomarkers seem destined to prove one of the major drivers of
pharmaceutical research and drug development in the 21st century," said Jon
Brett-Harris, EVP Pharmaceutical and Chemicals Markets, Thomson Reuters. "For
example, the presence of a specific antibody in the blood might indicate a
specific infection. Once an association between a biomarker and a disease is
clearly established, the one can be used to signal the other, and to a high
degree of certainty. As well, changes in the prevalence of a biomarker in the
organism can immediately and reliably signpost a patient's response to

    Some pharmaceutical companies are already advancing their research and
harnessing the power of biomarkers, which can:

    -- Be used to detect the predisposition for disease in a population,
       screen for its presence, confirm its diagnosis, assess its severity,
       predict its response to available therapies and measure its
       clinical course
    -- Be used as targets to discover new drugs
    -- Be a decisive factor in determining whether or not to continue
       research on an entity
    -- Show early in the development phase whether an entity could lead to
       side effects that should terminate further research
    -- Help to make clinical trials more efficient
    -- Reduce treatment overheads by optimizing dosages and measuring a
       patient's response more quickly and accurately

    It is believed that every drug process may have a number of biomarkers
associated with it. Most scientists already use a core set of biomarkers, but
this is insignificant when compared to the thousands of biomarkers that may
exist and have yet to be discovered, documented or quantified. The new
Thomson Reuters biomarker report suggests that the disease areas at the
forefront of the drive to discover new biomarkers are: cancer, cardiology,
neurology, and metabolic, autoimmune and inflammatory diseases.

    However, although biomarkers represent the future of drug development,
Thomson Reuters analysis has found broad differences in the Pharma industry's
approach to them. Some innovators have important biomarker research projects
progressing, while many others have yet to attempt any research at all.

    In spite of this, biomarkers are clearly at the top of the agenda for
regulatory authorities. The FDA has recognized that biomarkers are an area of
supreme importance to pharmaceutical innovation and personalized medicine and
is seeking to create a new framework for regulatory acceptance. Other
agencies, including the EMEA, are engaging with same process. In Japan, the
Ministry of Education, Culture, Sports, Science and Technology, and the
Ministry of Health, Labor and Welfare, have proposed biomarker development as
a national project, and are actively promoting biomarker research.

    To read the full report, "Establishing the Standards in Biomarker
Research", please register online at:

    The Scientific business of Thomson Reuters provides information and
knowledge to accelerate research, discovery and innovation. Its
authoritative, accurate and timely information is essential for drug
companies to discover new drugs and get them to market faster; researchers to
find relevant papers and know what's newly published in their subject; and
businesses to optimize their intellectual property and find competitive
intelligence. We create the research platforms and services of the future
that will power our customers toward business and personal success.

About Thomson Reuters

    Thomson Reuters is the world's leading source of intelligent information
for businesses and professionals. We combine industry expertise with
innovative technology to deliver critical information to leading decision
makers in the financial, legal, tax and accounting, scientific, healthcare
and media markets, powered by the world's most trusted news organization.
With headquarters in New York and major operations in London and Eagan,
Minnesota, Thomson Reuters employs more than 50,000 people in 93 countries.
Thomson Reuters shares are listed on the New York Stock Exchange (NYSE: TRI);
Toronto Stock Exchange (TSX: TRI); London Stock Exchange (LSE: TRIL); and
Nasdaq (NASDAQ: TRIN). For more information, go to

    Eoin Bedford
    PR Manager
    [email protected]

    Web site:


a d v e r t i s e m e n t